tetano
Editor, Senior Moderator
J Cardiovasc Pharmacol
. 2021 Apr 19.
doi: 10.1097/FJC.0000000000001041. Online ahead of print.
Pre-admission statin therapy and clinical outcome in hospitalized patients with COVID-19: an Italian multicenter observational study
Vincenzo Russo[SUP] 1 [/SUP], Angelo Silverio, Fernando Scudiero, Emilio Attena, Antonello D'Andrea, Luigi Nunziata, Guido Parodi, Dario Celentani, Ferdinando Varbella, Stefano Albani, Giuseppe Musumeci, Pierpaolo Di Micco, Marco Di Maio
Affiliations
Abstract
Statins therapy has been recently suggested as possible adjuvant treatment to improve the clinical outcome in patients with coronavirus disease 2019 (COVID-19). The aim of the present study was to describe the prevalence of pre-admission statin therapy in hospitalized patients with COVID-19 and to investigate its potential association with acute distress respiratory syndrome (ARDS) at admission and in-hospital mortality. We retrospectively recruited 467 patients with laboratory-confirmed COVID-19 admitted to the emergency department of 10 Italian hospitals. The study population was divided in two groups according to the ARDS diagnosis at admission and in-hospital mortality. A multivariable regression analysis was performed to assess the risk of ARDS at admission and death during hospitalization among COVID-19 patients. A competing risk analysis in patients taking or not statins before admission was also performed. ARDS at admission was reported in 122 cases (26.1%). There was no statistically significant difference in terms of clinical characteristics between patients presenting with and without ARDS. 107 patients (18.5%) died during the hospitalization; they showed increased age (69.6± 13.1vs 66.1± 14.9; P=0.001), coronary artery disease (23.4% vs 12.8%; P= 0.012) and chronic kidney disease (20.6% vs 11.1%; P= 0.018) prevalence; moreover, they presented more frequently ARDS at admission (48.6% vs 19.4%; P<0.001). At multivariable regression model statin therapy was not associated neither with ARDS at admission nor with in-hospital mortality. Pre-admission statins therapy does not seem to show a protective effect in severe forms of COVID-19 complicated by ARDS at presentation and rapidly evolving toward death.
. 2021 Apr 19.
doi: 10.1097/FJC.0000000000001041. Online ahead of print.
Pre-admission statin therapy and clinical outcome in hospitalized patients with COVID-19: an Italian multicenter observational study
Vincenzo Russo[SUP] 1 [/SUP], Angelo Silverio, Fernando Scudiero, Emilio Attena, Antonello D'Andrea, Luigi Nunziata, Guido Parodi, Dario Celentani, Ferdinando Varbella, Stefano Albani, Giuseppe Musumeci, Pierpaolo Di Micco, Marco Di Maio
Affiliations
- PMID: 34173802
- DOI: 10.1097/FJC.0000000000001041
Abstract
Statins therapy has been recently suggested as possible adjuvant treatment to improve the clinical outcome in patients with coronavirus disease 2019 (COVID-19). The aim of the present study was to describe the prevalence of pre-admission statin therapy in hospitalized patients with COVID-19 and to investigate its potential association with acute distress respiratory syndrome (ARDS) at admission and in-hospital mortality. We retrospectively recruited 467 patients with laboratory-confirmed COVID-19 admitted to the emergency department of 10 Italian hospitals. The study population was divided in two groups according to the ARDS diagnosis at admission and in-hospital mortality. A multivariable regression analysis was performed to assess the risk of ARDS at admission and death during hospitalization among COVID-19 patients. A competing risk analysis in patients taking or not statins before admission was also performed. ARDS at admission was reported in 122 cases (26.1%). There was no statistically significant difference in terms of clinical characteristics between patients presenting with and without ARDS. 107 patients (18.5%) died during the hospitalization; they showed increased age (69.6± 13.1vs 66.1± 14.9; P=0.001), coronary artery disease (23.4% vs 12.8%; P= 0.012) and chronic kidney disease (20.6% vs 11.1%; P= 0.018) prevalence; moreover, they presented more frequently ARDS at admission (48.6% vs 19.4%; P<0.001). At multivariable regression model statin therapy was not associated neither with ARDS at admission nor with in-hospital mortality. Pre-admission statins therapy does not seem to show a protective effect in severe forms of COVID-19 complicated by ARDS at presentation and rapidly evolving toward death.